Announcements Trials

Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Cardiotoxicity 6 Lymphoma, Non-Hodgkin 4 Lymphoma 3 Breast Neoplasms 3 Prostatic Neoplasms 2 Multiple Myeloma 2 Leukemia 2 Cardiovascular Diseases 2 Small Cell Lung Carcinoma 1 Obesity 1 Neoplasms 1 Neoplasm, Residual 1 Myelodysplastic Syndromes 1 Metastatic Solid Tumors 1 Metabolic Syndrome 1 Melanoma 1 Lymphoproliferative Disorders 1 Lymphomatoid Granulomatosis 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Primary Effusion 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1 Lymphoma, AIDS-Related 1 Lung Neoplasms 1 Leukemia, Hairy Cell 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Heart Failure 1 Epstein-Barr Virus Infections 1

Interventions

pembrolizumab 137 Nivolumab 116 Ipilimumab 68 Cyclophosphamide 33 Specimen Handling 31 Magnetic Resonance Spectroscopy 28 trametinib 23 binimetinib 22 fludarabine 21 Interleukin-2 20 dabrafenib 19 relatlimab 17 encorafenib 17 Biopsy 17 CTLA-4 Antigen 16 cemiplimab 15 atezolizumab 15 aldesleukin 15 Radiosurgery 15 fludarabine phosphate 14 Opdualag 14 Radiotherapy 11 lenvatinib 10 Blood Specimen Collection 10 lifileucel 9 Paclitaxel 8 Cisplatin 8 Bevacizumab 8 spartalizumab 7 cobimetinib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × Echocardiography × 1 year × Clear all

NCT06605833 2025-10-01

CARD-IO

Royal Marsden NHS Foundation Trust

Enrolling by invitation

Melanoma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡